Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know

Novavax stock closed at $10.11, up 1.1% and outpacing the S&P 500's 0.17% gain. However, the vaccine maker faces headwinds with projected quarterly revenue down 39.01% year-over-year and full-year revenue expected to decline 68.15%. The stock holds a Zacks Rank #3 (Hold) rating, with EPS estimates falling 7.86% over the past month.